Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

• Sponsor: Mylan Pharmaceuticals Inc (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00649493
• Collaborator: (none)
• Enrollment: 72
• Location: 1
• Arms: 2
• Duration (Months): 1
• Patients Per Site Per Month: 70.7

Study Details

Study Description

Brief Summary

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium 20 mg tablets to Eisai's Aciphex® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fed conditions.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: Rabeprazole Sodium Tablets 20 mg; Drug: Aciphex® Tablets 20 mg	Phase 1

Study Design

• Study Type: Interventional
• Actual Enrollment: 72 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Official Title: Single-Dose Food In Vivo Bioequivalence Study of Rabeprazole Sodium Tablets (20 mg; Mylan) and Aciphex® Tablets (20 mg; Eisai) in Healthy Volunteers
• Study Start Date: May 1, 2003
• Actual Primary Completion Date: Jun 1, 2003
• Actual Study Completion Date: Jun 1, 2003

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 Rabeprazole Sodium Tablets 20 mg	Drug: Rabeprazole Sodium Tablets 20 mg; 20mg, single dose fed
Active Comparator: 2 Aciphex® Tablets 20 mg	Drug: Aciphex® Tablets 20 mg; 20mg, single dose fed

Outcome Measures

Primary Outcome Measures

1. The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data. [blood collections through 24 hours]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 8 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• healthy, adult subjects, 18 years and older

• able to swallow medication

Exclusion Criteria:

• institutionalized subjects

• history of any significant disease

• use of any prescription or OTC medications within 14 days of start of study

• received any investigational products within 30 days prior to start of study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	PRACS Institute, Ltd.	Fargo	North Dakota	United States	58104

Sponsors and Collaborators

• Mylan Pharmaceuticals Inc

Investigators

• Principal Investigator: James D Carlson, Pharm. D., PRACS Institute Ltd.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Mylan Pharmaceuticals Inc. - Clinical Trial Results
• Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use
• Recalls, Market Withdrawals and Safety Alerts

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00649493
• Other Study ID Numbers: RABE-0326
• First Posted: Apr 1, 2008
• Last Update Posted: Nov 25, 2009
• Last Verified: Nov 1, 2009

• Additional relevant MeSH terms: Rabeprazole

Study Results

No Results Posted as of Nov 25, 2009